Related references
Note: Only part of the references are listed.Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia
Nelson Lee et al.
ANTIVIRAL THERAPY (2011)
Emerging Influenza Antiviral Resistance Threats
Frederick G. Hayden et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Dual Resistance to Adamantanes and Oseltamivir Among Seasonal Influenza A(H1N1) Viruses: 2008-2010
Tiffany G. Sheu et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus
Justin D. Hoopes et al.
PLOS ONE (2011)
Dynamics of Influenza Virus Infection and Pathology
Roberto A. Saenz et al.
JOURNAL OF VIROLOGY (2010)
Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro
Jack T. Nguyen et al.
PLOS ONE (2010)
Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance
Jesse D. Bloom et al.
SCIENCE (2010)
Modeling amantadine treatment of influenza A virus in vitro
Catherine A. A. Beauchemin et al.
JOURNAL OF THEORETICAL BIOLOGY (2008)
Neuraminidase inhibitor resistance in influenza: Assessing the danger of its generation and spread
Andreas Handel et al.
PLOS COMPUTATIONAL BIOLOGY (2007)
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia
Menno D. de Jong et al.
NATURE MEDICINE (2006)
Kinetics of influenza A virus infection in humans
Prasith Baccam et al.
JOURNAL OF VIROLOGY (2006)
Comparison of the mutation rates of human influenza A and B viruses
E Nobusawa et al.
JOURNAL OF VIROLOGY (2006)
Mathematical model of influenza A virus production in large-scale microcarrier culture
L Möhler et al.
BIOTECHNOLOGY AND BIOENGINEERING (2005)
Share Paper
